Es Hcm Ugps2 Dental Hygiene Monitor

---
name: es-hcm-ugps2-dental-hygiene-monitor
description: This skill advises regular visual examination of the mouth to monitor for osteonecrosis of the jaw and other dental issues in patients receiving antiresorptive agents. Trigger phrases include initiating bisphosphonate or denosumab therapy and requesting preventive dental care guidance.
---

# Monitor dental hygiene and oral health during antiresorptive therapy

## STEP 1 — Gather Information
Collect medication details (type, dose, start date), baseline oral health status (recent dental exam, symptoms such as pain, swelling, loose teeth, exposed bone), cancer type, renal function, vitamin D and glucocorticoid use, and patient‑reported oral discomfort.

## STEP 2 — Rule In / Rule Out
Determine if the patient is currently receiving or about to start an antiresorptive agent (IV bisphosphonate or denosumab). If no, follow routine dental care; if yes, proceed to next step.

## STEP 3 — Classify or Stratify
Assess for signs/symptoms suggestive of osteonecrosis of the jaw (exposed bone, persistent pain, swelling, infection, non‑healing extraction site). Classify as: (a) asymptomatic, or (b) symptomatic/suspicious.

## STEP 4 — Decide
For asymptomatic patients, schedule a routine visual dental exam every 6 months and reinforce oral hygiene instructions. For symptomatic/suspicious patients, refer promptly to a dentist or oral surgeon for evaluation, defer invasive dental procedures until assessed, and notify the oncology team.

## Clinical Guardrails / Mimics / Pitfalls
Do not delay dental evaluation for new oral pain or exposed bone; avoid extractions, implants, or bone surgery without prior dental/oncology consultation; do not assume absence of symptoms rules out ONJ; do not neglect vitamin D and calcium monitoring which influence bone health.

## Concrete Clinical Example
A 62‑year‑old woman with breast cancer–related HCM starts monthly denosumab. She reports mild gum soreness but no visible lesions. Step 1 confirms denosumab start and mild soreness. Step 2 confirms antiresorptive therapy. Step 3 classifies as symptomatic (oral discomfort). Step 4 leads to prompt dental referral; exam reveals early mucosal ulceration, no exposed bone; she receives improved oral hygiene instructions and follow‑up in 4 weeks.

**Source:** Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac621